← Back to Search

Other

Drug Combinations for Lymphoma

Phase 1
Waitlist Available
Research Sponsored by Celgene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 2-3 months until proof of tumor progression
Awards & highlights

Study Summary

This trial is testing different combinations of drugs to treat two types of lymphoma.

Who is the study for?
Adults over 18 with certain types of lymphoma (DLBCL or follicular) that have not responded well to standard treatments. They must have measurable disease, be in good physical condition, and meet specific blood test criteria. Men must agree to avoid donating sperm during and after the trial.Check my eligibility
What is being tested?
The study is testing combinations of new drugs (CC-122, CC-223, CC-292) with an existing drug called Rituximab for treating Diffuse Large B-cell Lymphoma and Follicular Lymphoma. It's the first time these combinations are being tested across multiple centers.See study design
What are the potential side effects?
Potential side effects may include reactions related to the immune system, digestive issues like pancreatitis or diarrhea, nerve damage symptoms such as peripheral neuropathy, changes in blood counts leading to increased infection risk or bleeding problems.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 2-3 months until proof of tumor progression
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 2-3 months until proof of tumor progression for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety
Secondary outcome measures
Efficacy
Pharmacokinetics - CC-223 and CC-292 interaction

Trial Design

4Treatment groups
Experimental Treatment
Group I: CC-292 + CC-223 +/- rituximabExperimental Treatment3 Interventions
CC-292 administered twice daily at 500 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days
Group II: CC-122 + rituximabExperimental Treatment2 Interventions
CC-122 administered orally once daily in combination with Rituximab.
Group III: CC-122 + CC-292 +/- rituximabExperimental Treatment3 Interventions
CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-292 administered orally twice daily at 500 mg with or without Rituximab administered by IV once every 28 days
Group IV: CC-122 + CC-223 +/- rituximabExperimental Treatment3 Interventions
CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rituximab
FDA approved
CC-223
Not yet FDA approved
Spebrutinib
Not yet FDA approved
Avadomide
Not yet FDA approved

Find a Location

Who is running the clinical trial?

CelgeneLead Sponsor
643 Previous Clinical Trials
129,937 Total Patients Enrolled
Michael Pourdehnad, MDStudy DirectorCelgene
1 Previous Clinical Trials
271 Total Patients Enrolled
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,520 Previous Clinical Trials
3,371,577 Total Patients Enrolled
~15 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top